NAMSNewAmsterdam Pharma Company N.V.
$21.58-19% 1Y
$21.58
$21.1452 weeks$41.45
The financials
NewAmsterdam Pharma Company N.V. by the numbers
NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of $3.7M in Q2 2026 (quarter ended Jun 30, 2026), down 81% from the same quarter a year earlier. That came with net loss of $64M. For the full year FY2025, revenue was $23M (−51% year on year) and net income −$204M. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $3.7M | $19M | −81% |
| Operating income | −$65M | −$36M | n/a |
| Net income | −$64M | −$17M | n/a |
| Diluted EPS | −$0.52 | −$0.15 | n/a |